tuberculosis%20-%20pulmonary
TUBERCULOSIS - PULMONARY
Tuberculosis (TB) suspect is any one who has signs or symptoms suggestive of TB (eg >2 weeks productive cough).
Definite TB is considered in patients with culture or molecular line probe assay positive for Mycobacterium tuberculosis, or in patients with at least 1 sputum smear positive for acid-fast bacilli.
TB cases are also classified based on the disease anatomical site, bacteriological results (including drug resistance), previous treatment history and patient's HIV status.
Pulmonary TB is a case of TB that involves the lung parenchyma.
Miliary TB is considered as PTB since lung lesions are also seen.
TB in the pleural effusion, mediastinal and/or hilar lymph nodes with no evidence of abnormalities in the chest x-ray are considered extrapulmonary TB.
Patients presenting with both PTB and extrapulmonary TB are classified as a case of PTB.

Monitoring

  • All patients should be monitored to assess response to treatment
  • Regular monitoring facilitates completion of treatment & permits identification & management of adverse reactions
  • Monthly monitoring of weight is important & will be the basis of dosage adjustment
  • Sputum smear exam is used to check response of patient to treatment
    • Sputum samples should be collected at each follow-up
    • Status of smear exam at the end of the intensive phase is a poor predictor of relapse
Sputum Smear Monitoring in New Pulmonary Tuberculosis (PTB) Patients
  • Sputum smear exam should be repeated at month 2, after the patient receives the last dose of intensive-phase treatment
  • If sputum smear is positive at month 2, sputum smear exam should be repeated at month 3
    • If negative, no further sputum monitoring is needed
  • If sputum smear is positive at month 3, culture & DST (line probe assay or Xpert MTB/RIF) should be done
    • Culture at this stage will detect resistance w/o waiting until the 5th month to change the regimen
    • Xpert MTB/RIF can detect Rifampicin resistance in sputum smear positive patients after >3 months
  • Treatment failure is considered if MDR-TB is detected (smear- or culture-positivity) at any point; change of treatment is recommended
Sputum Smear Monitoring in Previously Treated Pulmonary Tuberculosis (PTB) Patients on 8 Months Retreatment Regimen
  • Sputum smear exam should be repeated at month 3, after the patient receives the last dose of intensive-phase treatment
  • If sputum smear is positive at month 3, culture & DST should be done & repeat sputum smear exam is advised at month 5
  • If sputum smear is positive at month 5, culture & DST should be done & repeat sputum smear exam is advised at month 8
  • If sputum smear is positive at month 8, culture & DST should be done
  • Treatment failure is considered if MDR-TB is detected (smear- or culture-positivity) at any point; change of treatment is recommended
Possible Reasons for a Positive Sputum Smear at the End of Intensive Phase
  • Poor supervision & compliance of patient to the initial phase of therapy
  • Poor quality of anti-TB agents
  • Underdosage
  • Patient has extensive cavitation & heavy bacillary load that leads to slow resolution
  • Presence of comorbid conditions that interferes w/ treatment adherence or response
  • Presence of MDR-TB
  • Non-viable bacteria remains in microscopy

Managing Anti-Tuberculosis (TB) Drugs’ Side Effects

  • Patient who will have minor adverse effects is advised to continue the regimen & be given symptomatic treatment
  • Patient who will have major adverse effects is advised to discontinue the drug & be referred to a clinician/hospital for further evaluation & management

More Common Side Effects

  • Cutaneous reactions
    • Responsible drugs: Streptomycin, Isoniazid, Rifampicin, Pyrazinamide
    • For itching w/o rash & no other obvious cause: Give patient antihistamine, moisturizers & continue TB treatment while observing the patient
    • If rash develops: Discontinue all anti-TB drugs
      • Once resolved, anti-TB drugs should be re-introduced one by one at a lower dose & then gradually increased over 3 days
  • Deafness or dizziness or decreased urine output
    • Responsible drug: Streptomycin
    • Discontinue the drug
  • Drug-induced hepatitis
    • Responsible drugs: Isoniazid, Pyrazinamide, Rifampicin
      • Rifampicin can also cause asymptomatic jaundice w/o evidence of hepatitis
    • Discontinue all anti-TB drugs
    • If the patient is severely ill & unsafe to stop TB drugs, nonhepatotoxic agents (eg Streptomycin, Ethambutol & a fluoroquinolone) may be used
    • Once resolved, anti-TB drugs should be re-introduced one by one starting w/ Rifampicin & then Isoniazid after 3-7 days
      • If hepatitis w/ jaundice occurs during the intensive phase & then resolves, same drugs should be restarted but Pyrazinamide should be replaced w/ Streptomycin to complete the 2 months initial therapy followed by Rifampicin & Isoniazid for 6 months continuation therapy
      • If hepatitis w/ jaundice occurs during the continuation phase & then resolves, Isoniazid & Rifampicin should be restarted to complete the 4 months continuation therapy
  • Shock, purpura, acute renal failure
    • Responsible drug: Rifampicin
    • Discontinue the drug

Monitoring Multidrug-resistant Tuberculosis (MDR-TB) Patients

  • Close monitoring is important during treatment of MDR-TB patients
  • Sputum smear & culture should be done monthly until patient has smear & culture conversion (2 consecutive smears & cultures are negative)
  • After conversion, bacteriological monitoring is advised monthly for smears & quarterly for cultures
  • Monthly follow-up is advised until sputum conversion & then every 2-3 months thereafter
  • Weight should be recorded monthly
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
30 Apr 2016
New drug applications approved by US FDA as of 16 - 30 Apr 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
15 Jan 2017
New drug applications approved by US FDA as of 1 - 15 January 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
31 Oct 2016
New drug applications approved by US FDA as of 16 - 31 October 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Pearl Toh, 21 Jul 2016
Children with oral habits of thumb-sucking or nail-biting were less likely to develop allergic hypersensitivity later in life, according to a recent study.